Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer

Becky A S Bibby, Niluja Thiruthaneeswaran, Lingjian Yang, Ronnie R Pereira, Elisabet More, Darragh G McArt, Paul O'Reilly, Robert G Bristow, Kaye J Williams, Ananya Choudhury, Catharine M L West

Research output: Contribution to journalArticlepeer-review

134 Downloads (Pure)


BACKGROUND: The presence of hypoxia is a poor prognostic factor in prostate cancer and the hypoxic tumor microenvironment promotes radioresistance. There is potential for drug radiotherapy combinations to improve the therapeutic ratio. We aimed to investigate whether hypoxia-associated genes could be used to identify FDA approved drugs for repurposing for the treatment of hypoxic prostate cancer.

METHODS: Hypoxia associated genes were identified and used in the connectivity mapping software QUADrATIC to identify FDA approved drugs as candidates for repurposing. Drugs identified were tested in vitro in prostate cancer cell lines (DU145, PC3, LNCAP). Cytotoxicity was investigated using the sulforhodamine B assay and radiosensitization using a clonogenic assay in normoxia and hypoxia.

RESULTS: Menadione and gemcitabine had similar cytotoxicity in normoxia and hypoxia in all three cell lines. In DU145 cells, the radiation sensitizer enhancement ratio (SER) of menadione was 1.02 in normoxia and 1.15 in hypoxia. The SER of gemcitabine was 1.27 in normoxia and 1.09 in hypoxia. No radiosensitization was seen in PC3 cells.

CONCLUSION: Connectivity mapping can identify FDA approved drugs for potential repurposing that are linked to a radiobiologically relevant phenotype. Gemcitabine and menadione could be further investigated as potential radiosensitizers in prostate cancer.

Original languageEnglish
Article number96
JournalBMC urology
Issue number1
Publication statusPublished - 1 Jul 2021

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre


Dive into the research topics of 'Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer'. Together they form a unique fingerprint.

Cite this